$HPCO needs $MMMW for low cost power for the company’s expansion plan. $HPCO is part of an industry that uses a lot of electricity.

Cannabis $HPCO Hempacco and Snoop Dogg Created Joint Venture to Launch Consumer Goods Powerhouse of Hemp and Hemp-Derived Products https://www.newsfilecorp.com/release/153326/Hempacco-and-Snoop-Dogg-Create-Joint-Venture-to-Launch-Consumer-Goods-Powerhouse-of-Hemp-and-HempDerived-Products

$MULN and $MMMW quality stocks. $MMMW high quality new technologies should attract the world class investors like $MULN institutional investor base. $MMMW market cap is about $2.5 million which is now below their radar.

$MULN Top Institutional Holders
Holder Shares Date Reported % Out Value
Vanguard Group, Inc. (The) 3,300,134 Mar 30, 2023 1.91% 1,387,376
Blackrock Inc. 2,948,405 Mar 30, 2023 1.71% 1,239,509
Geode Capital Management, LLC 1,033,755 Mar 30, 2023 0.60% 434,590
State Street Corporation 833,909 Mar 30, 2023 0.48% 350,575
Northern Trust Corporation 385,227 Mar 30, 2023 0.22% 161,949
Susquehanna International Group, LLP 212,458 Mar 30, 2023 0.12% 89,317
Price (T.Rowe) Associates Inc 191,256 Mar 30, 2023 0.11% 80,404
Bank Of New York Mellon Corporation 175,038 Mar 30, 2023 0.10% 73,585
Charles Schwab Investment Management, Inc. 119,376 Mar 30, 2023 0.07% 50,185
Morgan Stanley 68,268 Mar 30, 2023 0.04% 28,699
Top Mutual Fund Holders
Holder Shares Date Reported % Out Value
Vanguard Total Stock Market Index Fund 36,210,051 Dec 30, 2022 0.95% 15,222,705
iShares Russell 2000 ETF 8,034,431 Feb 27, 2023 0.21% 3,377,674
Vanguard Extended Market Index Fund 5,555,957 Dec 30, 2022 0.15% 2,335,724
Fidelity Small Cap Index Fund 2,709,810 Jan 30, 2023 0.07% 1,139,204
iShares Russell 2000 Growth ETF 2,565,431 Feb 27, 2023 0.07% 1,078,507
Fidelity Extended Market Index Fund 1,980,221 Feb 27, 2023 0.05% 832,484
Vanguard Balanced Index Fund 1,251,900 Dec 30, 2022 0.03% 526,298
Fidelity NASDAQ Composite Index Fund 934,355 Feb 27, 2023 0.02% 392,802
Vanguard Institutional Index-Inst Total Stock Market Ind 895,569 Dec 30, 2022 0.02% 376,497
SSgA SPDR ETFS Europe I-SPDR Russell 2000 US Small Cap UCITS ETF 867,800 Mar 30, 2023 0.02% 364,823

$ASTI and $MMMW heating to be solar hot.

$MULN cash and $MMMW June 29 big news.

$muln Total Cash (mrq) $60.34M

$MMMW with today’s news could bounce.

$MMMW with today’s news could bounce.

$ASTI HEATING UP ON CHINA NEWS WEEEEEEEeeeeeeee

$UURAF Ucore Rare Metals Inc., a junior exploration company, engages in the exploration of rare earth elements in Canada and the United States. It primarily holds a 100% interest in the Bokan Mountain/Dotson Ridge property located on Prince of Wales Island, Alaska. The company was formerly known as Ucore Uranium Inc. and changed its name to Ucore Rare Metals Inc. in June 2010. Ucore Rare Metals Inc. is headquartered in Halifax, Canada. http://finance.yahoo.com/quote/UURAF/profile?p=UURAF

ABBA's Benny Andersson and Bjorn Ulvaeus join Simon Fuller for dinner in London after it's announced they're working on a 'groundbreaking venture' PLFX

http://www.dailymail.co.uk/tvshowbiz/article-3929878/ABBA-s-Benny-Andersson-Bjorn-Ulvaeus-join-Simon-Fuller-dinner-London-s-announced-working-groundbreaking-venture.html

Be ready.....very ready

Evening Mick, be ready PLFX

part two/ The Heroin Vaccine That Could Save ‘Quadrillions’ On Healthcare Costs
By All That Is Interesting on July 17, 2015

http://all-that-is-interesting.com/heroin-vaccine

http://all-that-is-interesting.com/heroin-vaccine/2

The Heroin Vaccine That Could Save ‘Quadrillions’ On Healthcare Costs
By All That Is Interesting on July 17, 2015

Money as the Great Equalizer
The next step for Janda and his team of researchers is to secure investigational new-drug status from the FDA, which would allow them to conduct human trials. They’ve already received funding from the National Institute of Drug Abuse to the tune of $27.1 million—but that’s not enough to cover the cost of human trials.

And that brings us to a pretty embarrassing point: we live in the richest and most powerful country on earth. Janda and his team have stumbled onto something here that could change life in America in untold ways, and still they struggle with pedestrian concerns like money.

Think about it: without addiction, we’d make fewer arrests; our jails would be emptier; our cops would be less distracted with hunting and imprisoning drug addicts; our courts would be greatly unburdened, and we could turn our attention toward treatment instead of the jail-first-and-ask-questions-later approach we have now. In short: we could stop treating addicts like criminals and treat them instead like human beings with a disease.



[-chart]all-that-is-interesting.com/wordpress/wp-content/uploads/2015/07/Needle-Exchange.jpg[/chart]

Can we even put a price tag on that? According to the Affordable Care Act, the answer is no. As far back as December 2014, it was being reported that provisions in the still-new law would require non-grandfathered health plans to provide services recommended by the U.S. Preventive Services Task Force. Although the ACA is still clearly in its infancy, it seems to have laid the groundwork for more widespread coverage of preventive medicine—including, perhaps, vaccines like Janda’s.

But I can hear you already: Addiction is a choice—not a disease! Sure; it may start as a choice, as many things do, but neither you, nor I, nor anybody else, has a comprehensive understanding of what happens in the brain between that first “taste” of heroin and full-blown addiction. And that makes the management of America’s various addictions a job for scientists—not for cops.

The good news is that, in the world of pharmaceutical and health technology, sometimes all it takes is for one company, or even one person, to say or do something that captures the attention of the world.

In the fight against aggressive robo-calls, for example, all it takes is one frustrated plaintiff. And in the worldwide effort to rid the world of addiction, that one pivotal person may well turn out to be Kim Janda.

At the end of the day, acknowledging a degree of fluidity in the way we respond to national health crises could help us save an incredible amount of money. George Koob, who has been at Janda’s side throughout these vaccine trials probably said it best:

“I am not sure Americans realize that if they treated alcoholism and drug addiction they would save quadrillions of dollars in health care costs.”
So if we can’t answer to our hearts, maybe we can at least answer to our wallets.

part one/ The Heroin Vaccine That Could Save ‘Quadrillions’ On Healthcare Costs
By All That Is Interesting on July 17, 2015

http://all-that-is-interesting.com/heroin-vaccine

Kim Janda. Source: Robert Benson
You’d think it would be a big deal if a scientist created a vaccine that could do away with addiction. So what if I told you that we already had one?
Kim Janda has a vaccine for heroin addiction. And for meth. And for cocaine, too. Janda, an American chemist and the Ely R. Callaway, Jr. Chaired Professor at the Scripps Research Institute in La Jolla, California, gets calls and emails all the time from addicts, and people who know addicts, and who want more information about getting involved with clinical trials.
The problem? There haven
’t been any clinical trials. And there won’t be any for the foreseeable future, either.
Says Janda: “No pharmaceutical company is going to fund trials for heroin, no way … Forget about it.”

Though he’s worked on vaccines for a variety of addictions, he says the one for heroin shows the most promise. In 2013, he carried out pre-clinical trials on rats that had, ahem, developed an addiction to heroin. After they were given the vaccine, the rats exhibited a dramatic reversal: upon receiving the vaccine, these “addiction immune” rats could be injected with 10 times the dose of heroin that a “normal” rat could handle—without any ill effects whatsoever.
So what does this mean for human beings? Nothing yet, and that’s a big problem.

How Big Is Our Heroin Problem?
In America, our failed drug policies have actually contributed to a dramatic rise in heroin addiction and overdose. Painkiller abuse is frequently cited as a potential “gateway” to heroin use, which makes the 259 million painkiller prescriptions filed each year even more dubious. In 2014, the CDC estimated that 46 Americans die from painkiller overdoses every day.



[-chart]all-that-is-interesting.com/wordpress/wp-content/uploads/2015/07/Heroin-Graph.jpg[/chart]

So why would a painkiller abuser “graduate” to heroin? It’s pretty simple: heroin is cheaper. And you don’t need a prescription to get it.

Existing Solutions
Janda’s vaccines are not the first attempt to curb addiction with pharmaceuticals, but they’re almost certainly the most promising. The FDA has already approved a variety of drugs to treat withdrawal symptoms—a baby step, to be sure—but the drugs themselves pose a danger of dependency and withdrawal. You might recognize some of the names, including naltrexone, acamprosate, and buprenorphine.
The short version is that they’re far from perfect.

Adding to Janda’s setbacks were lackluster results from a nicotine vaccine study in 2011 and a cocaine vaccine study in 2014—two failures that, unfortunately, seem to have convinced pharmaceutical companies that research of this kind is a dead-end.

The tricky part of a vaccine like this is the fact that drugs wreak havoc on the brain’s reward systems—neurological impulses that the human body relies on for survival. Any attempt at a vaccine must seek to curb the effect of what these drugs are doing without causing new neurological problems. Existing pharmaceutical solutions address addiction by blocking the relevant receptors in the brain. Janda’s vaccine works instead by preventing the drug from reaching the brain in the first place.

TIME Magazine phrases the mechanics of Janda’s vaccine as simply as possible: it essentially works like a sponge; it waits in the blood stream to intercept drug molecules, ensuring that their journey is a short one. The brain never even registers the drug’s presence. In short, it’s the most efficient solution to the addiction problem we’ve seen yet.

part six / cimavax drug interaction , said F.D.A. APPROVAED HERE
http://www.rxlist.com/script/main/art.asp?articlekey=199476

https://en.wikipedia.org/wiki/CimaVax-EGF

https://www.roswellpark.org/cancertalk/201603/where-does-cimavax-currently-stand

=====================================================

Lung Cancer Vaccine Gets FDA Approval — And You’ll Never Guess Who Made It
By Michael Gardiner on October 28, 2016

http://all-that-is-interesting.com/lung-cancer-vaccine

CIMAvax treats non-small cell lung cancer, which accounts for 80 to 85 percent of diagnoses.

The U.S. Food and Drug Administration (FDA) has recently approved a clinical trial for a lung cancer vaccine, brought to the U.S. by an ostensibly unlikely source: Cuba.

New York Gov. Andrew Cuomo announced that the FDA authorized initial trials for the lung cancer drug CIMAvax at a press conference this past Wednesday. Roswell Park Cancer Institute will conduct the trials in partnership with CIMAvax’s namesake, Cuba’s Centro de Inmunologia Molecular (CIM), in Buffalo, New York.

If all goes well, U.S. patients will have access to this revolutionary drug, which holds promise for treating certain breast, head and neck, and colorectal cancers as well.

Most promising at the moment, however, is CIMAvax’s ability to treat non-small cell lung cancer (NSCLC), which accounts for roughly 80 to 85 percent of lung cancer diagnoses and is commonly found in non-smokers. Small cell lung cancer (SCLC), or the other 10 to 15 percent, is a separate disease with different genetic markers, and is the lung cancer that is chiefly attributable to smoking.

Already produced in Cuba for $1 per dose by a state-owned biotech firm, CIMAvax will treat NSCLC by prompting the immune system to attack a protein that promotes cancer cell growth.

While CIMAvax doesn’t cure the cancer, the vaccine does make the condition much more manageable. Researchers have compared its effectiveness to the current treatments for high blood pressure or diabetes that don’t cure those conditions but do significantly ameliorate them — which CIMAvax has already done for thousands of people.

“To date, CIMAvax has been administered to 5,000 patients across the world, including 1,000 Cubans,” wrote Kelvin Lee, the immunology department chair at the Roswell Park Cancer Institute.


“Expansive clinical trials have been underway for some time now, with published data showing prolonged life (especially in patients [less than] 60 yrs old, with a mean overall survival of 18.53 months in the vaccinated patients compared to 7.55 months for the unvaccinated patients) when compared to standard care, with minimal vaccine-related toxicity.”

This collaboration between the U.S. and Cuba has only recently become possible due to the embargo exemption the U.S. Treasury announced earlier this month in conjunction with President Obama’s decision to lift restrictions blocking U.S. and Cuban medical researchers from working together.

Cuban pharmaceutical companies are now allowed to apply for FDA clinical trial permission.

Next, learn exactly what cancer is before reading about the heroin vaccine that could save “quadrillions in healthcare costs.”

part five/ cimavax drug interaction
http://www.rxlist.com/script/main/art.asp?articlekey=199476

https://en.wikipedia.org/wiki/CimaVax-EGF

https://www.roswellpark.org/cancertalk/201603/where-does-cimavax-currently-stand

https://www.roswellpark.org/cancertalk/201611/3-innovations-cuban-lung-cancer-vaccine

patent ?????
http://vacunascontracancer.com/home/

part four/ cimavax drug interaction
http://www.rxlist.com/script/main/art.asp?articlekey=199476

https://en.wikipedia.org/wiki/CimaVax-EGF


The US Food and Drug Administration has approved a US clinical trial of a lung cancer vaccine developed in Cuba.

New York Governor Andrew Cuomo announced the approval on October 26 at a press conference at the Roswell Park Cancer Institute in Buffalo, where the trial will be conducted.

The vaccine, CimaVax, was developed for non–small cell lung cancer (NSCLC) and has been available in Cuba since 2011.

The newly approved study will be phase 1/2 trial of CIMAvax in combination with the anti-PD1 checkpoint inhibitor nivolumab (Opdivo, Bristol-Myers Squibb) in patients previously treated for advanced NSCLC. Roswell Park anticipates that the trial will take 3 years to complete and will enroll 60 to 90 patients.

CimaVax targets the epidermal growth factor receptor (EGFR), which is overexpressed in approximately 40% to 80% of NSCLCs. EGFR overexpression is associated with poor prognosis, lower survival, and resistance to therapy in cancer. The vaccine's mechanism of action is to prevent binding of the endogenous epidermal growth factor (EGF) to the receptors, thus denying tumors the growth factor.

The vaccine has been in development for 25 years. Studies have shown it yields a survival advantage in comparison with supportive care. Despite some mainstream news hype about CIMAvax, the benefit seen so far is not considered to be game changing, as previously reported by Medscape Medical News.

To date, CIMAvax has been used to treat about 4000 patients worldwide. It is approved for use in Bosnia and Herzegovina, Colombia, Cuba, Paraguay, and Peru, according to the Roswell Park Institute website.

In a phase 3 trial, patients with advanced disease who had been vaccinated had a significant improvement in median overall survival in comparison with control patients who received best supportive care (12.4 months vs 9.4 months; weighted log rank, P = 0.04) (Clin Cancer Res. 2016;22:3782-3790). The researchers noted that the median survival (14.6 months) was longer in vaccinated patients who had high EGF concentration at baseline.

A US lung cancer specialist cautions that the expectations about this vaccine should not be overblown.

"It seems to provide a very modest survival benefit," said Jack West, MD, of the Swedish Cancer Institute in Seattle in an online forum held this past summer.

Dr West was commenting on some of the media hype about the vaccine that emerged earlier this year. "As a rule, you don't need to debate whether something is a breakthrough years after it has been used routinely in another part of the world for many years," he said.

According to Roswell Park press materials, CIMAvax may also prove effective in treating colon, head and neck, prostate, breast, and pancreatic cancers.

SOURCES:

FDA Approves US Trial of Cuban Lung Cancer Vaccine. Medscape. Oct. 31, 2016.

part three/ CimaVax DRUG/ AT YHOO/ CimaVax DRUG/ sounds like in u.s.a. now.

https://search.yahoo.com/search?p=+CimaVax+DRUG&fr=uh3_finance_vert&fr2=p%3Afinvsrp%2Cm%3Asb

http://www.medicaldaily.com/cimavax-cuban-lung-cancer-vaccine-gets-approval-come-us-what-if-we-could-prevent-332968

http://www.medicaldaily.com/

http://www.medicaldaily.com/innovation

http://www.medicaldaily.com/innovation

http://www.medicaldaily.com/under-hood

http://www.medicaldaily.com/hill


Cimavax, Cuban Lung Cancer Vaccine, Gets Approval To Come To US: What If We Could Prevent Cancer?
May 12, 2015 01:45 PM By Dana Dovey @danadovey d.dovey@medicaldaily.com

Thanks to improved relations with Cuba, U.S. researchers will soon have access to a lung cancer vaccine. The Roswell Park Cancer Institute in New York has finalized an agreement with Cuba’s Center for Molecular Immunology to bring the vaccine, Cimavax, to the United States.

Cimavax has now embarked on the first leg of its long journey to FDA approval. Although the drug has been available free of charge to Cubans since 2011, it will likely be some time before Americans can expect the treatment to be available stateside. Roswell Park CEO Dr. Candace Johnson told Wired that she hopes to get approval for testing Cimavax within six to eight months and to start clinical trials in a year.

Once trials begin, the vaccine will need to be tested for its safety and effectiveness before its release for public use can even be discussed. The process will likely take years, but still, Roswell Park has already submitted a 1,000-page investigational new drug (IND) application for FDA review, Johnson previously told Medical Daily.
Although many may confuse vaccines as a drug which prevents an illness, the word actually describes anything which facilitates an immune response from the body. Cimavax works by spurring a patient’s body to release antibodies against epidermal growth factor, which signals tumor growth. In lung cancer patients, this prevents lung tumors from growing and spreading and can turn a late-stage lung cancer into something slightly more manageable.

According to Cancer Research UK, the vaccine helps lung cancer patients live an average of four to six months longer than those without the medication. It also improved the people’s quality of life by reducing symptoms such as coughing and breathlessness.

The drug is by far not a miracle solution to lung cancer. It does not save the lives of terminal lung cancer patients. It can only extend and slightly improve them. Also, there are already treatments available in the U.S., such as the widely used Tarceva, which works similar to Cimavax by extending patient lifespan by controlling tumor growth hormones. However, Cimavax is particularly intriguing because of its low toxicity level and extreme affordability (Wired reported that each shot of the drug costs the Cuban government around one U.S. dollar).

Roswell Park doesn’t plan on limiting its Cimavax research to lung cancer treatment, however. The institute is hoping to take the vaccine to the next level and explore its potential as a way to completely prevent the recurrence and even initial onset of lung cancer. Currently, the drug is given to help extend the lives of lung cancer patients in Cuba. Roswell Park plans on testing the limits of the drug’s capacity and what would happen if the drug was given to individuals who do not yet have lung cancer tumors. For example, in a talk radio show with WBFO, Johnson explained her interest in seeing if the drug could prevent the recurrence of lung cancer in patients that were diagnosed early on, had surgery to remove the cancer, but still remain at high risk.

“You have surgery. You treat the lung cancer. You're free of disease, but you're at high risk for recurrence. The cancer is going to grow back. Let's give the vaccine there,” Johnson said.

She even wants to push the vaccine’s potential even further and explore whether actually preventing cancer from ever occurring is a real possibility.

“And let's just say that works and we prevent recurrence and we show an efficacy in that setting,” she said. “We could move back even further, and perhaps this vaccine may have value in treating heavy smokers or people with already chronic lung diseases that are at high risk for lung cancer.”

part two/ i will read/ Cuba’s Had A Lung Cancer Vaccine For Years, And Now It’s Coming To The U.S.
By Erin Schumaker , Anna Almendrala

http://www.huffingtonpost.com/2016/02/22/cuba-lung-cancer-vaccine_n_7267518.html

In addition to CimaVax, Roswell Park scientists are also reviewing other vaccine approaches from researchers at Cuba’s Center of Molecular Immunology (where CimaVax was invented) that could one day help patients overcome brain and pancreas cancer, as well as blood cancers like leukemia and lymphoma. While they aren’t as far along as CimaVax, Johnson said she is excited for the possibility these other treatments hold.

“They are a very innovative group of scientists, and they have vaccines and drugs that we think could play a very significant role in our fight against cancer,” she said. “We’re delighted to be working with them and we hope very soon that we can start our trial on CimaVax — hopefully the first of many clinical trials to be done with some of these Cuban vaccine approaches.”

To be clear, the CimaVax doesn’t cure cancer. It’s a therapeutic vaccine that works by targeting the tumor itself, specifically going after the proteins that allow a tumor to keep growing. (And as PBS points out, a person can’t just take a shot of CimaVax and continue to smoke without fear of lung cancer.)

“We hope to determine in the next few years whether giving CimaVax to patients who’ve had a lung cancer removed, or maybe even to people at high risk of developing lung or head-and-neck cancers because of a history of heavy smoking, may be beneficial and may spare those people from having a cancer diagnosis or recurrence,” Lee said.

What needs to happen first

Roswell Park faces many bureaucratic hurdles before clinical trials for CimaVax actually begin.

Because an embargo on Cuba is still in effect, Roswell Park had to apply for a license from the Office of Foreign Assets Control at the Treasury Department to bring CimaVax into the U.S. The license allows them to use it for lab research, but not to give it out to patients, Johnson explained.

Then, in order to start testing CimaVax on Americans, Roswell Park has to get approval for a trial from the U.S. Food and Drug Administration. Currently, Roswell Park and the FDA are communicating about the design of the trial, Johnson said.

Once the FDA signs off, Johnson has to submit the project to Roswell Park’s Scientific Review Committee to evaluate its scientific merit, as well as their Institutional Review Board, a body that evaluates the ethical aspects of any medical research involving human subjects. These two final processes alone can take months to complete, Johnson said, and she hopes to start on Phase 1 and II clinical trials, which assess the effectiveness and safety of a drug, sometime in 2016. The entire process, from start to finish, can take years to complete — even when the experimental drug was invented in the U.S.

To that end, the United States is currently at work developing two lung cancer vaccines of its own, GVAX and BLP 25, though neither has been studied for as long as CimaVax.

Cuba’s public health record

How does a tiny island nation with limited economic resources pioneer a powerhouse cancer vaccine? “They’ve had to do more with less,” Johnson told Wired in May. “So they’ve had to be even more innovative with how they approach things. For over 40 years, they have had a preeminent immunology community.”

Despite decades of economic problems and the U.S. trade embargo, Cuba has been a model of public health. According the New York Times, life expectancy for Cubans is 79 years, on par with the United States, despite the fact that its economy per person is eight times smaller. While many drugs and even anesthesia have been hard to come by over the years, Cuba has one of the best doctor to patient ratios in the world. Moreover, the Cuban government’s investment in primary care for residents and preventative health measures like public education, housing and nutrition have paid huge dividends in the health of citizens, especially relative to similarly poor countries.

Looking forward, ongoing research collaborations between the two nations are almost certainly on the horizon as relations between Cuba and the U.S. continue to thaw. For now, Lee says the researchers at Roswell Park have their eyes trained on about 20 cancer treatment and prevention technologies in Cuba — including another lung cancer vaccine called racotumomab that the group hopes to study in clinical trials at Roswell.

This story, originally published in May 2015, was updated throughout with new information about CimaVax and U.S.-Cuba relations in February 2016.

part one/ i will read/ Cuba’s Had A Lung Cancer Vaccine For Years, And Now It’s Coming To The U.S.
By Erin Schumaker , Anna Almendrala

http://www.huffingtonpost.com/2016/02/22/cuba-lung-cancer-vaccine_n_7267518.html

President Barack Obama became the first president to visit Cuba in almost 90 years when he and first lady Michelle Obama traveled to the island nation in March. But one of the most exciting things about the thawing of relations between Cuba and the U.S. is happening stateside right now: the possibility of clinical trials on a drug to prevent lung cancer, and possibly other cancers, too.

CimaVax, which is both a treatment and vaccine for lung cancer, has been researched in Cuba for 25 years and free to the Cuban public since 2011. New York Governor Andrew Cuomo’s trade mission to Cuba in April 2015 resulted in a signed agreement to bring CimaVax to the U.S., but as with all international drugs and treatments, U.S. researchers need to conduct clinical trials and replicate international scientists’ results before it becomes available to the American public.

“We’re still at the very early stages of assessing the promise of this vaccine, but the evidence so far from clinical trials in Cuba and Europe has been striking,” said Dr. Kelvin Lee, Jacobs Family Chair in Immunology and co-leader of the Tumor Immunology and Immunotherapy Program at Roswell Park Cancer Institute in Buffalo, New York, the research center that is evaluating CimaVax for U.S. use.

The hoped-for success of CimaVax availability in the U.S. is just one example of the possibilities that come with open trade between the two nations. When Obama loosened the United State’s 55-year trade embargo against Cuba in December, he allowed for such joint research deals to be finalized. Similar programs might have been impossible just a few years ago.

“You never know how long these things would take,” said Candace Johnson, CEO of Roswell Park. “We would have loved to have had this already started because we’ve been working on this for quite a while, but we’re persistent and we’ll get it done.”

Cuba has long been known for its high-quality cigars, and lung cancer is a major public health problem and the fourth-leading cause of death in the country. A 2007 study of patients with stages IIIB and IV lung cancer, published in the Journal of Clinical Oncology, confirmed the safety of the CimaVax and showed an increase in tumor-reducing antibody production in more than half of cases. It proved particularly effective for increased survival if the study participant was younger than 60.

So far, 5,000 patients worldwide have been treated with CimaVax, including 1,000 patients in Cuba. Lee said the latest Cuban study of 405 patients, which has not yet been published, confirms earlier findings about the safety and efficacy of the vaccine. What’s more, the shot is cheap — each costs the Cuban government just $1, Wired reported. Studies have found there are no significant side effects.

“We think it may be an effective way to prevent cancer from developing or recurring, so that’s where a lot of our team’s excitement comes in,” Lee said. “There’s good reason to believe that this vaccine may be effective in both treating and preventing several types of cancer, including not only lung but breast, colorectal, head-and-neck, prostate and ovarian cancers, so the potential positive impact of this approach could be enormous.”

How it works

CimaVax induces people to build antibodies against a certain growth factor that cancer cells make. For people who already have lung cancer, this response results in the body actually getting rid of the cancer cells. And for people who are currently healthy but at high risk for lung cancer — say, a lung cancer patient in remission — the treatment acts as a vaccine to prevent future relapse. Johnson envisions that it could one day be a standard preventive vaccine that a person gets in childhood, much like the way we get vaccinated against polio, measles, mumps and rubella.

$PLFX HUGE READING/ good morning/ my friend/ been car busy/

PLFX Formal launch of ABBA, Elvis and Michael Jackson are expected to launch world wide tours any day. PLFX owns the rights and is the leading in Augmented Reality bringing these artist back to stage. Early estimates in the billions for revenue.

Will Revising Dodd-Frank Send the Markets Soaring? 7 YRS. ????? 53,496 PAGES ?????

It has been nearly seven years since Dodd-Frank was signed into law,
but some of the rules still haven’t been finalized and implemented.

Whatever your view about the necessity for the regulations and the need for placing a tighter belt around Wall Street,
there is something wildly inefficient about taking seven years to implement rules.

The confusion and complexity of the entire process has arguably been
more detrimental to banks and
financial institutions than the rules themselves.

Consider this fact as relayed from the Banking Compliance Index:
since January 2013,
banks and credit unions alone have dealt with 1207 new rules spanning

53,486 pages in the Federal Register. Read that again:
53,486 pages of rules! Now imagine trying to run your business,

but then having a government agency hand you a 50,000-page rule book.

“Frustrating” would not be an adequate way to describe the difficulty of doing business. It’s beyond that.

+++++/ PART TWO/ Why JetBlue Could be the Next Tesla
Jeff Siegel Photo By Jeff Siegel
Written Tuesday, April 11, 2017
http://www.energyandcapital.com/articles/investing-in-electric-airplanes/5795

After the global economy came to a crashing halt in 2008, I started cherry-picking stocks that I knew wouldn’t be kept down long.

A Recipe for Success

I can’t speak for every airline, but there’s one company that has been quietly investing in a new type of airplane that could actually eliminate jet fuel costs entirely. And since fuel accounts for about 20% of operating expenses for most airlines, this is a very big deal.

A few weeks ago, I told you about how Airbus (OTCBB: EADSY) and Siemens (OTCBB: SIEGY) were actively developing electric planes that will one day accommodate short, regional flights.

Here’s a picture of an electric aircraft using a Siemens electric motor:



[-chart]images.angelpub.com/2017/14/43258/siep.jpg[/chart]

NOW ????? airline's ????? future ?????



[-chart]images.angelpub.com/2017/14/43259/jbep.png[/chart]


In just a few years, this electric plane could be flying the friendly skies. And JetBlue (NASDAQ: JBLU) is backing this little beauty.


Along with Boeing (NYSE: BA), JetBlue Technology Ventures, which is JetBlue's investing unit, is ponying up big time to help a small startup called Zunum Aero get this thing properly tested, into production, and in the air.

Utilizing an electric plane like the one being developed by Zunum Aero could not only eliminate fuel costs, but, according to engineers, also cut travel time by 50%.

Shorter flights, zero fuel costs, higher margins — this is a recipe for success.

Now, while it’s still early in the development of electric airplanes, let me remind you that just 10 years ago, this is what one of the most popular electric cars looked like:

earlier


[-chart]images.angelpub.com/2017/14/43260/zzap.jpg[/chart]

TODAY 2017


[-chart]images.angelpub.com/2017/14/43261/tspop.jpg[/chart]

Jeff is the founder and managing editor of Green Chip Stocks, a private investment community that capitalizes on opportunities in alternative energy, organic food markets, legal cannabis, and socially responsible investing. He has been a featured guest on Fox, CNBC, and Bloomberg Asia, and is the author of the best-selling book, Investing in Renewable Energy: Making Money on Green Chip Stocks.

+++++/ PART ONE/ Why JetBlue Could be the Next Tesla
Jeff Siegel Photo By Jeff Siegel
Written Tuesday, April 11, 2017
http://www.energyandcapital.com/articles/investing-in-electric-airplanes/5795

After the global economy came to a crashing halt in 2008, I started cherry-picking stocks that I knew wouldn’t be kept down long.

GE (NYSE: GE), Whole Foods (NASDAQ: WFM), and Southwest Airlines (NYSE: LUV) were among the biggest winners for me. The latter was one I actually felt a little nervous about, though. After all, airline stocks can be particularly risky.

But in the case of Southwest, I knew it was a solid play in the industry. Despite the various hills and valleys along the way, Southwest has always maintained a business model that just works. Zero pretentiousness, cheap fares, and excellent customer service.

Over the years, I’ve watched so many other airlines struggle, implementing new fees and running all kinds of lame gimmicks. Yet rarely do they improve profitability.

Now, one thing the airline industry does have going for it at the moment is low oil prices. High fuel costs can absolutely crush margins, so the respite from high oil prices over the past couple of years has offered some much-needed breathing room. And this will likely continue for the next year or two.

But at some point, those prices are going to creep back up. So it should come as no surprise that some airlines are looking for new ways to implement a better hedge against the inevitable.

GOOD EVENING ALL , INTELLECTUAL STOCK INVESTOR

$LVGI LIMITLESS HEALTH LVGI


?* Prostaderol the all natural prostate health supplement.
* LipiRestorin
?* Maxtlevelin help maximize your testosterone levels.

You are most welcome!
Happy valentines

$AVXL

FROM MICK AND MOD'S, happy valentine's day. 02-14-2017

thank you, happy valentine's day.

$AVXL
http://noble.mediasite.com/mediasite/Play/2451c4d03e624780a689acb83b9ddbe81d

this is ah great team , PMCB

Four Horsemen Documentary
Strange Things
Strange Things

The Best UFO Sightings from the last few years
Strange Things
Strange Things

UFO, how it works Lets go inside of alien spaceship
Strange Things
Strange Things

Alien Crashes SOLID EVIDENCE UFO Documentary
Strange Things
Strange Things

Top Secret - Kapustin Yar Russia's Area 51 - Documentary
Strange Things
Strange Things

Best Documentary 2017 - Top SECRET DARPA Projects | America's Advanced Military Weapons | Documentar
John C. Durham
John C. Durham

SECRET ????? / (NEW) Top Secret Advanced Military Weapons 2017 HD
Daily Military Updates
Daily Military Update

U.S. Navy's Future Technology (Trillion Dollar Defence) #Mind Blow Full Documentary
Daily Military Updates
Daily Military Updates

[DARPA] MOST ADVANCED WEAPONS - HD Documentary
ADVEXON TV
ADVEXON TV

DARPA's EXACTO smart bullet hits again and again: DT Daily
Digital Trends
Digital Trends

16 seconds Secret: How to choose between two guys! ? 7 second of happiness™ FUNNY Video ?
Jo 7 seconds of happiness
Jo 7 seconds of happiness

DEADLIEST Snipers Of All Time!
Origins Explained
Origins Explained

GERMAN ????? WW-2 ?????/ Most BIZARRE Weapons Ever!
Origins Explained
Origins Explained

Most AMAZING Military Vehicles!
Origins Explained
Origins Explained

The Most Dangerous Military Vehicles And Aircrafts
TheRichest
TheRichest

MACH 7/ Top Secret Advanced Military Weapons/ELECTRO MAGNETIC
TheRichest
TheRichest

9 WEAPONS/ SCIFI Weapons That Actually EXIST!
Origins Explained
Origins Explained

#3/ US Latest Technology - XM307 Advanced Crew Served Weapon
Pak Pasban
Pak Pasban